ATRA (Atara Biotherapeutics) Total Liabilities: $57.31 Mil (As of Mar. 2026)


ATRA Atara Biotherapeutics Inc ATRA
29 GF Score
Price $10.48
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Total Liabilities?

Atara Biotherapeutics ATRA +0.34% 29 Total Liabilities is $57.31 Mil as of Mar. 2026. GuruFocus rates ATRA with a GF Score™ of 29/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Atara Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $57.31 Mil.

Atara Biotherapeutics's quarterly Total Liabilities declined from Sep. 2025 ($66.80 Mil) to Dec. 2025 ($58.74 Mil) and declined from Dec. 2025 ($58.74 Mil) to Mar. 2026 ($57.31 Mil).

Atara Biotherapeutics's annual Total Liabilities declined from Dec. 2023 ($264.74 Mil) to Dec. 2024 ($206.38 Mil) and declined from Dec. 2024 ($206.38 Mil) to Dec. 2025 ($58.74 Mil).

Atara Biotherapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Total Liabilities Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 188.51 249.78 264.74 206.38 58.74

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.11 71.94 66.80 58.74 57.31
ATRA
29GF Score
Atara Biotherapeutics Inc ATRA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Atara Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.922+(9.347+34.468
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=58.74

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=20.235--38.502
=58.74

Atara Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.645+(9.076+42.588
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=57.31

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=19.997--37.312
=57.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $57.31 Mil mean?
Atara Biotherapeutics (ATRA) has a Total Liabilities of $57.31 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Total Liabilities too high?
Atara Biotherapeutics' current Total Liabilities is $57.31 Mil. Overall, Atara Biotherapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Total Liabilities compare to ANIX and BMEA?
Atara Biotherapeutics' Total Liabilities of $57.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Total Liabilities is $57.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.48 — trading 571.8% above its estimated fair value. The current Total Liabilities is $57.31 Mil. Atara Biotherapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Total Liabilities is $57.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $10.48 is trading 571.8% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Total Liabilities: $57.31 Mil
  • GF Value™: $1.56 vs. price of $10.48 (571.8% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
29GF Score

Get the complete analysis for ATRA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.48
Price
$1.56
GF Value